High-dose vitamin C as a targeted treatment for KRAS-driven cancers?
Elisabeth Mack(Universitätsklinikum Gießen und Marburg), Andreas Neubauer(RWTH Aachen University), Cornelia Brendel(Philipps University of Marburg), Frank Willeke(University of Siegen), Christian Hohl(University of Siegen), Jonas Schäfer(Philipps University of Marburg), Peer Bredow(University of Siegen), Albert Grass(Philipps University of Marburg), Cornelia Otet(University of Siegen), Carsten Denkert(Philipps University of Marburg)
Cited by 3
Related Papers
Pembrolizumab for Early Triple-Negative Breast Cancer
|New England Journal of Medicine|2020|3.1k
Diverse Applications of Nanomedicine
|ACS Nano|2017|1.4k
Tumor infiltrating lymphocytes are prognostic in triple negative breast cancer and predictive for trastuzumab benefit in early breast cancer: results from the FinHER trial
|Annals of Oncology|2014|1.3k
Gilteritinib or Chemotherapy for Relapsed or Refractory <i>FLT3</i> -Mutated AML
|New England Journal of Medicine|2019|1.3k